Patents Assigned to Hoffmann-La Roche Inc.
  • Publication number: 20220184216
    Abstract: The present invention relates to conjugates comprising a small molecule targeting ligand and a cargo molecule.
    Type: Application
    Filed: March 3, 2020
    Publication date: June 16, 2022
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Ashwath JAYAGOPAL, Kameron V. KILCHRIST, Martin G. NUSSBAUMER
  • Publication number: 20220187256
    Abstract: The invention relates to a chromatography method of producing a target elution volume comprising a first and a second target protein. The method includes providing a cation exchange chromatography column; applying a protein solution on the column, the protein solution comprising the first target protein, a second target protein and optionally one or more further proteins; inputting an optimization criterion; computing chromatography simulations for computing an elution buffer salt concentration adapted to provide a target elution volume matching the optimization criterion best; computing the pooling borders of the target elution volume as a function of at least the computed salt concentration and the input optimization criterion; applying an elution buffer having the computed salt concentration on the chromatography column; performing the elution; and collecting the computed target elution volume.
    Type: Application
    Filed: February 18, 2022
    Publication date: June 16, 2022
    Applicant: HOFFMANN-LA ROCHE INC.
    Inventors: Andreas SCHAUBMAR, Felix WITTKOPP
  • Patent number: 11357914
    Abstract: A multi chamber syringe unit includes a body, a separating element and a bypass arrangement. The body has a distal end side, a proximal end side opposite to the distal end side, an interior limited by a side wall between the distal end side and the proximal end side and a longitudinal axis centrally extending from the distal end side to the proximal end side through the body. The separating element is arranged in the interior of the body forming a distal chamber between the distal end side and the separating element and a proximal chamber between the proximal end side and the separating element. The bypass arrangement is a section of the body in which the interior has a constant noncircular cross section orthogonal to the longitudinal axis. The multi camber syringe unit allows for being efficiently prepared and for efficiently providing or administering high quality of prefilled products.
    Type: Grant
    Filed: February 3, 2017
    Date of Patent: June 14, 2022
    Assignee: HOFFMANN-LA ROCHE INC.
    Inventors: Jörg Lümkemann, Tobias Werk
  • Patent number: 11359026
    Abstract: The problem to be solved is to provide a humanized anti-IL-6 receptor antibody MRA-containing formulation which is suitable for subcutaneous administration, wherein dimerization or deamidation is prevented during long-term storage. The present application is directed to a stable antibody-containing liquid formulation characterized by containing arginine and histidine buffer. A method of inhibiting deamidation or dimerization of such an antibody in a concentrated liquid formulation includes histidine buffer in the liquid formulation.
    Type: Grant
    Filed: April 27, 2021
    Date of Patent: June 14, 2022
    Assignees: CHUGAI SEIYAKU KABUSHIKI KAISHA, HOFFMANN-LA ROCHE INC.
    Inventors: Toshiyuki Morichika, Daisuke Kameoka, Yoshimi Imaeda, Terutoshi Maeda, Oliver Boris Stauch
  • Patent number: 11358962
    Abstract: The invention relates to small molecule imaging tools, specifically compounds of formula II and to pharmaceutically acceptable acid addition salts thereof, wherein R1-R6 have any of the values defined in the specification.
    Type: Grant
    Filed: October 16, 2018
    Date of Patent: June 14, 2022
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Edilio Borroni, Luca Gobbi, Michael Honer, Henner Knust, Matthias Koerner, Dieter Muri
  • Patent number: 11360085
    Abstract: Herein is reported a method for determining bacterial endotoxin at low concentrations in a sample of an antibody (that has been produced using bacterial cells) comprising the following steps in the following order: i) adding magnesium ions to the sample, ii) diluting the sample, iii) dialyzing the sample having a pH-value of 5.7-8.0 against an endotoxin-flee aqueous solution, and iv) determining bacterial endotoxin in the sample using a bacterial endotoxin test, particularly the Limulus amoebocyte lysate assay.
    Type: Grant
    Filed: January 28, 2020
    Date of Patent: June 14, 2022
    Assignees: Forschungszentrum Borstel Leibniz Lungenzentrum, Hoffmann-La Roche Inc.
    Inventors: Christian Alexander, Sven Deutschmann, Pierre Lang, Friedrich Von Wintzingerode, Ulrich Zaehringer
  • Publication number: 20220177884
    Abstract: The present invention relates to antisense oligonucleotides that are capable of modulating expression of Tau in a target cell. The oligonucleotides hybridize to MAPT mRNA. The present invention further relates to conjugates of the oligonucleotide and pharmaceutical compositions and methods for treatment of Tauopathies, Alzheimer's disease, fronto-temporal dementia (FTD), FTDP-17, progressive supranuclear palsy (PSP), chronic traumatic encephalopathy (CTE), corticobasal ganglionic degeneration (CBD), epilepsy, Dravet syndrome, depression, seizure disorders and movement disorders.
    Type: Application
    Filed: January 21, 2022
    Publication date: June 9, 2022
    Applicant: HOFFMANN-LA ROCHE INC.
    Inventors: Peter HAGEDORN, Anja Mølhart HØG, Marianne L. JENSEN, Richard E. OLSON
  • Patent number: 11352330
    Abstract: The invention provides novel compounds having the general formula (I) wherein RA, RB, RC, RC1 and W are as defined herein, compositions including the compounds and methods of using the compounds.
    Type: Grant
    Filed: March 6, 2020
    Date of Patent: June 7, 2022
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Jerome Hert, Daniel Hunziker, Holger Kuehne, Thomas Luebbers, Rainer E. Martin, Patrizio Mattei, Werner Neidhart, Hans Richter, Markus Rudolph, Emmanuel Pinard
  • Publication number: 20220168418
    Abstract: The present invention relates to the prevention or mitigation of adverse effects related to T cell engaging agents, such as cytokine release syndrome. Specifically, the invention relates to the prevention or mitigation of such side effects using an inhibitor of JAK and/or mTOR.
    Type: Application
    Filed: November 9, 2021
    Publication date: June 2, 2022
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Hélène Cécile HAEGEL, Christian KLEIN, Gabrielle LECLERCQ, Alberto TOSO, Tina ZIMMERMANN
  • Publication number: 20220169639
    Abstract: The present invention provides the compounds having the general formula: (I) wherein R1 to R8, and X are as described herein, compositions including the compounds and methods of using the compounds.
    Type: Application
    Filed: December 11, 2019
    Publication date: June 2, 2022
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Song FENG, Jiamin ZHENG, Yongfu LIU, Dongdong CHEN, Hong SHEN, Xuefei TAN
  • Publication number: 20220169729
    Abstract: Herein is reported a method for producing a trivalent antibody comprising the steps of cultivating a mammalian cell comprising a deoxyribonucleic acid encoding the trivalent antibody, and recovering the trivalent antibody from the cell or the cultivation medium, wherein the deoxyribonucleic acid encoding the trivalent antibody is stably integrated into the genome of the mammalian cell and comprises in 5?- to 3?-direction a first expression cassette encoding the first heavy chain, a second expression cassette encoding the first light chain, a third expression cassette encoding the first light chain, a fourth expression cassette encoding the second heavy chain, a fifth expression cassette encoding the second light chain, and a sixth expression cassette encoding the second light chain, wherein the first heavy chain comprises from N- to C-terminus a first heavy chain variable domain, a CH1 domain, a first light chain variable domain, a CH1 domain, a hinge region, a CH2 domain and a CH3 domain, the second heavy ch
    Type: Application
    Filed: December 16, 2021
    Publication date: June 2, 2022
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Johannes Auer, Monika Fruehschuetz, Ulrich Goepfert, Christina-Lisa Hoeck
  • Publication number: 20220169599
    Abstract: The present invention provides new arylsulfonamide compounds having the general formula (I) wherein L, R1, R2, R3 and R4 are as described herein, compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds.
    Type: Application
    Filed: February 15, 2022
    Publication date: June 2, 2022
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Barbara BIEMANS, Luca GOBBI, Georg JAESCHKE, Henner KNUST, Lothar LINDEMANN, Fionn O'HARA, Jean-Marc PLANCHER
  • Publication number: 20220169731
    Abstract: Herein is reported a method for producing a multivalent, bispecific antibody comprising the steps of cultivating a mammalian cell comprising a deoxyribonucleic acid encoding the multivalent, bispecific antibody, and recovering the multivalent, bispecific antibody from the cell or the cultivation medium, wherein the deoxyribonucleic acid encoding the multivalent, bispecific antibody is stably integrated into the genome of the mammalian cell and comprises in 5?- to 3?-direction a first expression cassette encoding the first heavy chain, a second expression cassette encoding the first light chain, a third expression cassette encoding the first light chain, a fourth expression cassette encoding the second heavy chain, a fifth expression cassette encoding the first light chain, and a sixth expression cassette encoding the first light chain, wherein the first heavy chain comprises from N- to C-terminus a first heavy chain variable domain, a CH1 domain, a first heavy chain variable domain, a CH1 domain, a hinge regi
    Type: Application
    Filed: December 16, 2021
    Publication date: June 2, 2022
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Johannes Auer, Monika Fruehschuetz, Christina-Lisa Hoeck
  • Publication number: 20220168307
    Abstract: The present invention relates to 7-(4,7-diazaspiro[2.5]octan-7-yl)-2-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)pyrido[1,2-a]pyrimidin-4-one for use in the treatment of spinal muscular atrophy (SMA), its pharmaceutical composition to be used in the treatment of SMA, its methods of treatment thereof.
    Type: Application
    Filed: December 10, 2021
    Publication date: June 2, 2022
    Applicant: Hoffmann-La Roche Inc.
    Inventor: Heidemarie Kletzl
  • Publication number: 20220169730
    Abstract: Herein is reported a method for producing a bivalent, bispecific antibody comprising the steps of cultivating a mammalian cell comprising a deoxyribonucleic acid encoding the bivalent, bispecific antibody, and recovering the bivalent, bispecific antibody from the cell or the cultivation medium, wherein the deoxyribonucleic acid encoding the bivalent, bispecific antibody is stably integrated into the genome of the mammalian cell and comprises in 5?- to 3?-direction either a first expression cassette encoding the first light chain, a second expression cassette encoding the first heavy chain, a third expression cassette encoding the second light chain, and a fourth expression cassette encoding the second heavy chain, or a first expression cassette encoding the first light chain, a second expression cassette encoding the second heavy chain, a third expression cassette encoding the second light chain, and a fourth expression cassette encoding the first heavy chain, wherein the first heavy chain comprises from N- t
    Type: Application
    Filed: December 16, 2021
    Publication date: June 2, 2022
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Johannes Auer, Simon Auslaender, Monika Fruehschuetz, Ulrich Goepfert, Christina-Lisa Hoeck
  • Publication number: 20220170115
    Abstract: The present invention relates to means and methods for determining whether a patient is in need of a PD-L1 inhibitor cotherapy. A patient is determined to be in need of the PD-L1 inhibitor cotherapy if a low or absent ER expression level and an expression level of programmed death ligand 1 (PD-L1) that is increased in comparison to a control is measured in vitro in a sample from the patient. The patient is undergoing therapy comprising a modulator of the HER2/neu (ErbB2) signaling pathway (like Trastuzumab) and a chemotherapeutic agent (like dodetaxel) or such a therapy is contemplated for the patient. Also provided herein are means and methods for treating a cancer in a cancer patient for whom therapy comprising a modulator of the HER2/neu (ErbB2) signaling pathway (like Trastuzumab) and a chemotherapeutic agent (like dodetaxel) is contemplated, wherein the patient is to receive PD-L1 inhibitor cotherapy.
    Type: Application
    Filed: February 17, 2022
    Publication date: June 2, 2022
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Anton Belousov, Giampaolo Bianchini, Luca Gianni, Marlene Thomas
  • Publication number: 20220170049
    Abstract: Herein is reported a method for producing a recombinant mammalian cell comprising a deoxyribonucleic acid encoding a polypeptide and secreting the polypeptide comprising the steps of a) providing a mammalian cell comprising an exogenous nucleotide sequence integrated at a single site within a locus of the genome of the mammalian cell, wherein the exogenous nucleotide sequence comprises a first and a second recombination recognition sequence flanking at least one first selection marker, and a third recombination recognition sequence located between the first and the second recombination recognition sequence, and all the recombination recognition sequences are different; b) introducing into the cell provided in a) a composition of two deoxyribonucleic acids comprising three different recombination recognition sequences and one to eight expression cassettes, wherein the first deoxyribonucleic acid comprises in 5?- to 3?-direction, a first recombination recognition sequence, one or more expression cassette(s), a
    Type: Application
    Filed: December 16, 2021
    Publication date: June 2, 2022
    Applicant: Hoffmann-La Roche Inc.
    Inventor: Simon Auslaender
  • Publication number: 20220170893
    Abstract: A chromatography system comprising a mixing circuit or a mixing chamber, a bubble trap, a concentration detector and one or more pumps, characterized in that the bubble trap has a permanent opening at its highest point is described herein. Furthermore, a chromatography system is described, characterized in that it contains two concentration detectors the first of which is located in the mixing circuit or the mixing chamber and the second is located downstream of the main pump.
    Type: Application
    Filed: November 11, 2021
    Publication date: June 2, 2022
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Andreas BLASCHYK, Darko DVEKAR, Christian SCHMALZ
  • Patent number: 11345708
    Abstract: The present invention relates to compounds of formula I wherein L is a bond, a triple bond, —C(O)NH— or —NHC(O)—; R1 is phenyl or a five or six-membered heteroaryl group, optionally substituted by lower alkyl, lower alkyl substituted by halogen or lower alkoxy substituted by halogen; R2 is fluoro; R3 is fluoro or chloro; R4 is hydrogen, lower alkyl, halogen, lower alkyl substituted by hydroxy, S(O)2CH3, or is a five or six-membered heteroaryl group or a heterocycloalkyl group, which are optionally substituted by lower alkyl, hydroxy or ?O; R5 and R6 are both methyl and the dotted line is a bond, or R5 and R6 are both methyl and the dotted line is nothing, or one of R5 and R6 is hydrogen and the other is methyl, and the dotted line is nothing; or to a pharmaceutically acceptable salt or acid addition salt, to all possible tautomeric forms, to a racemic mixture, or to its corresponding enantiomer and/or optical isomer and/or stereoisomer thereof.
    Type: Grant
    Filed: February 13, 2020
    Date of Patent: May 31, 2022
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Georg Jaeschke, Fionn O'Hara, Eric Vieira
  • Patent number: D954092
    Type: Grant
    Filed: July 31, 2020
    Date of Patent: June 7, 2022
    Assignees: Hoffmann-La Roche Inc., Roche Molecular Systems, Inc.
    Inventors: Jorge Cancela Gonzalez, Geraint Iwan Davies, Jean-Philippe Guy Roger Guyon, Christin Rene Kreml, Tommy Park